Description

PENTALOC 40 MG (1X15)

Indications

PENTALOC 40 MG is primarily indicated for the treatment of various gastrointestinal disorders. It is commonly prescribed for conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The medication helps reduce gastric acid secretion, thereby alleviating symptoms associated with excessive acid production and promoting healing of the gastric mucosa.

Mechanism of Action

PENTALOC contains the active ingredient pantoprazole, which is a proton pump inhibitor (PPI). It works by irreversibly inhibiting the hydrogen-potassium ATPase enzyme system (the proton pump) located in the gastric parietal cells. By blocking this enzyme, pantoprazole effectively reduces the secretion of gastric acid. This action results in decreased acidity in the stomach, allowing for the healing of damaged tissues and relief from symptoms associated with acid-related disorders.

Pharmacological Properties

PANTALOC exhibits a rapid onset of action, with peak plasma concentrations typically reached within 2 to 4 hours after oral administration. The bioavailability of pantoprazole is approximately 77% after a single dose, and it is extensively metabolized in the liver via the cytochrome P450 system, primarily through CYP2C19 and CYP3A4 enzymes. The elimination half-life is about 1 hour, but the duration of acid suppression lasts significantly longer due to the irreversible binding of the drug to the proton pump. PANTALOC is primarily excreted in the urine as metabolites, with less than 1% of the unchanged drug being eliminated.

Contraindications

PENTALOC is contraindicated in patients with a known hypersensitivity to pantoprazole or any of the excipients in the formulation. It should also be avoided in individuals with severe liver impairment, as the drug is metabolized in the liver and may lead to increased plasma concentrations. Additionally, caution is advised in patients with a history of gastric malignancy, as the treatment may mask symptoms of underlying conditions.

Side Effects

Common side effects associated with PENTALOC may include headache, diarrhea, nausea, vomiting, abdominal pain, and flatulence. While these side effects are generally mild and transient, some patients may experience more serious adverse effects such as hypersensitivity reactions, liver enzyme elevations, and gastrointestinal infections. Long-term use of PPIs has also been associated with an increased risk of bone fractures, Clostridium difficile infection, and vitamin B12 deficiency. Patients should be monitored for these potential complications, especially during prolonged therapy.

Dosage and Administration

The recommended dosage of PENTALOC for adults is typically 40 mg once daily, administered orally. For the treatment of GERD and peptic ulcers, the duration of therapy may range from 4 to 8 weeks, depending on the clinical response and physician’s discretion. In patients with Zollinger-Ellison syndrome, higher doses may be required, and the treatment may be continued for an extended period. It is important to take PENTALOC before meals for optimal absorption. The tablets should be swallowed whole with water and should not be crushed or chewed.

Interactions

PANTALOC may interact with various medications due to its effect on gastric pH and its metabolism through the cytochrome P450 system. Drugs that require an acidic environment for absorption, such as ketoconazole and atazanavir, may have reduced bioavailability when taken concurrently with PENTALOC. Additionally, medications that are metabolized by CYP2C19, such as clopidogrel, may have altered effects when used with pantoprazole. It is essential for healthcare providers to review a patient’s complete medication list to identify potential interactions and adjust therapy accordingly.

Precautions

Patients should be advised to use PENTALOC with caution if they have a history of liver disease, as dosage adjustments may be necessary. It is also important to consider the potential for vitamin B12 deficiency with long-term use, as the drug may impair absorption. Regular monitoring of magnesium levels is recommended in patients on prolonged therapy, as hypomagnesemia has been reported with PPI use. Pregnant and breastfeeding women should consult their healthcare provider before using PENTALOC, as the safety profile in these populations has not been fully established.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy of PENTALOC in managing acid-related disorders. In a randomized controlled trial involving patients with GERD, pantoprazole was shown to significantly reduce symptoms and heal esophageal mucosal damage compared to placebo. Other studies have confirmed its effectiveness in promoting ulcer healing and reducing the recurrence of peptic ulcers when used in combination with antibiotics for H. pylori eradication. The safety profile of PENTALOC has also been evaluated in long-term studies, indicating that it is generally well-tolerated with a low incidence of serious adverse effects.

Conclusion

PENTALOC 40 MG is a valuable therapeutic option for patients suffering from various gastrointestinal disorders related to excessive gastric acid production. Its mechanism of action as a proton pump inhibitor provides effective symptom relief and promotes healing of the gastric mucosa. While generally well-tolerated, healthcare providers should remain vigilant for potential side effects and drug interactions. Individualized patient care, including monitoring and education, is essential for optimizing treatment outcomes with PENTALOC.